ArticleCellular & molecular immunology2020
Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients.
Open access · hybridAbstract read
In one paragraph
Article in Cellular & molecular immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
1.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 59 citations in OpenAlex.
- Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).Revista da Sociedade Brasileira de Medicina Tropical · 2023Trial
- Article
- The effect of therapeutic plasma exchange on the inflammatory response in septic shock: a secondary analysis of the EXCHANGE-1 trial.Intensive care medicine experimental · 2025Article
- Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.BMC infectious diseases · 2024Article
- Integrated analysis of RNA-seq datasets reveals novel targets and regulators of COVID-19 severity.Life science alliance · 2024Article
- Frequency of HLA-DRThe Journal of allergy and clinical immunology · 2024Article
- COVID severity test (CoST sensor)-An electrochemical immunosensing approach to stratify disease severity.Bioengineering & translational medicine · 2023Article
- Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID.Vaccines · 2023Review
- Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25Cellular immunology · 2023Article
- Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study.Nature communications · 2022Article
- Immune system-related soluble mediators and COVID-19: basic mechanisms and clinical perspectives.Cell communication and signaling : CCS · 2022Review
- COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.International immunopharmacology · 2022Review
- Article
- Cytokines from Bench to Bedside: A Retrospective Study Identifies a Definite Panel of Biomarkers to Early Assess the Risk of Negative Outcome in COVID-19 Patients.International journal of molecular sciences · 2022Observational
- Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients.Viruses · 2022Article
- The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.Signal transduction and targeted therapy · 2022Review
- Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients.Cytokine · 2022Article
- Article
- A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults.Clinical immunology (Orlando, Fla.) · 2021Article
- Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression.Molecular immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Yaguang Zhang *State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.ORCID http://orcid.org/0000-0002-2417-6516
Xiaojing Wang *Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.
Xuezhen Li *State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Dong Xi *Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.
Ruizhi MaoClinical Research Center and Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 200030, Shanghai, China.
Xiaohui WuClinical Research Center and Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 200030, Shanghai, China.
Shipeng ChengState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Xiaoyu SunState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Chunyan YiState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Zhiyang LingState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Liyan MaState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China.
Qin NingDepartment and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China.ORCID http://orcid.org/0000-0002-8748-9085
Yiru FangClinical Research Center and Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 200030, Shanghai, China. yirufang@aliyun.com.
Bing SunState Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, 200031, Shanghai, China. bsun@sibs.ac.cn.
Di WuDepartment and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China. woody_1984@163.com.ORCID http://orcid.org/0000-0002-2027-9593
Chinese Academy of Sciences · CNTongji Hospital · CNShanghai Jiao Tong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BetacoronavirusLymphopeniaB-LymphocytesCoronavirus InfectionsCOVID-19Healthy VolunteersHLA-DR AntigensHumansInterleukin-2Interleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma SubunitPandemicsPneumonia, ViralSARS-CoV-2SolubilityHLA-DR AntigensIL2 protein, humanIL2RA protein, humanIL2RB protein, humanIL2RG protein, humanInterleukin-2Interleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.